Young Suk Park

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1806086/publications.pdf

Version: 2024-02-01

181 papers	4,636 citations	185998 28 h-index	123241 61 g-index
183 all docs	183 docs citations	183 times ranked	8274 citing authors

#	Article	IF	Citations
1	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2427-2435.	1.2	5
2	Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study. Gastroenterology, 2022, 162, 509-520.e7.	0.6	23
3	Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study. Cancer Research and Treatment, 2022, 54, 1240-1255.	1.3	4
4	Phase 1b study of vactosertib in combination with nal-IRI plus 5FU/LV in patients with metastatic pancreatic ductal adenocarcinoma who have failed first-line gemcitabine/nab-paclitaxel.. Journal of Clinical Oncology, 2022, 40, TPS632-TPS632.	0.8	2
5	Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study. European Journal of Cancer, 2022, 163, 119-127.	1.3	12
6	HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer. Frontiers in Oncology, 2022, 12, 834104.	1.3	6
7	Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	1.2	0
8	Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing. Journal of Oncology, 2022, 2022, 1-9.	0.6	7
9	Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer. Annals of Surgical Oncology, 2022, , 1.	0.7	1
10	ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer. Annals of Surgical Oncology, 2022, , .	0.7	0
11	Light-to-Moderate Alcohol Consumption Increases the Risk of Biliary Tract Cancer in Prediabetes and Diabetes, but Not in Normoglycemic Status: A Nationwide Cohort Study. Journal of Clinical Oncology, 2022, 40, 3623-3632.	0.8	3
12	Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07. Journal of Clinical Oncology, 2022, 40, 3868-3877.	0.8	6
13	Phase 1b study of vactosertib in combination with oxaliplatin with 5FU/LV (FOLFOX) in patients with metastatic pancreatic cancer who have failed first-line gemcitabine/nab-paclitaxel.. Journal of Clinical Oncology, 2022, 40, e16299-e16299.	0.8	1
14	Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. Oncology, 2021, 99, 365-372.	0.9	6
15	Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. Journal of Cancer, 2021, 12, 460-466.	1.2	4
16	Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT). Oncologist, 2021, 26, e954-e962.	1.9	14
17	A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. Investigational New Drugs, 2021, 39, 1335-1347.	1.2	1
18	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Clinical Cancer Research, 2021, 27, 4700-4709.	3.2	54

#	Article	IF	Citations
19	Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer.. Journal of Clinical Oncology, 2021, 39, 3573-3573.	0.8	18
20	A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. Investigational New Drugs, 2021, 39, 1624-1632.	1.2	0
21	Clinical Outcomes of Neoadjuvant Chemotherapy in Colorectal Cancer Patients With Synchronous Resectable Liver Metastasis: A Propensity Score Matching Analysis. Annals of Coloproctology, 2021, 37, 244-252.	0.5	13
22	Impact of UGT1A1 genotype on the efficacy and safety of irinotecanâ€based chemotherapy in metastatic colorectal cancer. Cancer Science, 2021, 112, 4669-4678.	1.7	8
23	Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study. Metabolism: Clinical and Experimental, 2021, 123, 154848.	1.5	16
24	ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy. In Vivo, 2021, 35, 499-505.	0.6	1
25	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199299.	1.4	20
26	Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110384.	1.4	10
27	74â€…Tumor microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the response of MSS mCRC patients treated vactosertib in combination with pembrolizumab. , 2021, 9, A82-A82.		2
28	823â€…Spatial analysis of tumor-infiltrating lymphocytes correlates with the response of metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab. , 2021, 9, A861-A861.		0
29	Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer. Technology in Cancer Research and Treatment, 2021, 20, 153303382110623.	0.8	11
30	Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. Targeted Oncology, 2020, 15, 67-73.	1.7	1
31	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092679.	1.4	9
32	Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors. Expert Opinion on Investigational Drugs, 2020, 29, 1059-1067.	1.9	2
33	Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096584.	1.4	8
34	A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases. Clinical Colorectal Cancer, 2020, 19, e140-e150.	1.0	9
35	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. Translational Cancer Research, 2020, 9, 3367-3374.	0.4	26
36	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. Pathology Research and Practice, 2020, 216, 152820.	1.0	6

#	Article	IF	Citations
37	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. Journal of Oncology, 2020, 2020, 1-8.	0.6	7
38	Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. Targeted Oncology, 2020, 15, 185-192.	1.7	5
39	332â€...Novel TGF-Î² signatures in metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab. , 2020, , .		3
40	A clinical scoring system for survival prediction in advanced gastric cancer.. Journal of Clinical Oncology, 2020, 38, 436-436.	0.8	0
41	Pemetrexed plus erlotinib as a salvage treatment in high EGFR-expressing metastatic colorectal cancer patients following failure of standard chemotherapy: A phase II single-arm prospective study.. Journal of Clinical Oncology, 2020, 38, 104-104.	0.8	0
42	Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer. Cancer Research and Treatment, 2020, 52, 446-454.	1.3	5
43	The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. OncoTargets and Therapy, 2019, Volume 12, 225-231.	1.0	4
44	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. Journal of Cancer, 2019, 10, 3140-3144.	1.2	5
45	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. Cancer Discovery, 2019, 9, 1388-1405.	7.7	155
46	Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. Journal of Clinical Oncology, 2019, 37, 3111-3123.	0.8	100
47	Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. Scientific Reports, 2019, 9, 15365.	1.6	54
48	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. Translational Oncology, 2019, 12, 597-601.	1.7	8
49	Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system. PLoS ONE, 2019, 14, e0215080.	1.1	2
50	Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study . OncoTargets and Therapy, 2019, Volume 12, 1717-1728.	1.0	13
51	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. Journal of Cancer, 2019, 10, 1611-1615.	1.2	7
52	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. Frontiers in Oncology, 2019, 9, 1327.	1.3	5
53	Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. Journal of Cancer, 2019, 10, 6185-6190.	1.2	7
54	The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma. Pathology Research and Practice, 2019, 215, 171-176.	1.0	17

#	Article	IF	Citations
55	Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy. Surgery, 2019, 165, 579-585.	1.0	25
56	Anastomotic Leak Does Not Impact Oncologic Outcomes After Preoperative Chemoradiotherapy and Resection for Rectal Cancer. Annals of Surgery, 2019, 269, 678-685.	2.1	37
57	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. Journal of Clinical Oncology, 2019, 37, 3104-3104.	0.8	2
58	The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. Korean Journal of Internal Medicine, 2019, 34, 165-177.	0.7	20
59	A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Cancer Research and Treatment, 2019, 51, 1128-1134.	1.3	12
60	Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Nodeâ€"Positive Gastric Cancer Treated with Different Adjuvant Protocols. Cancer Research and Treatment, 2019, 51, 876-885.	1.3	8
61	Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapeIRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial.. Journal of Clinical Oncology, 2019, 37, 711-711.	0.8	0
62	Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs. Translational Cancer Research, 2019, 8, 2107-2112.	0.4	0
63	Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. American Journal of Translational Research (discontinued), 2019, 11, 4508-4515.	0.0	4
64	MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis. Molecular Cancer Therapeutics, 2018, 17, 838-848.	1.9	36
65	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. Clinical Colorectal Cancer, 2018, 17, 140-146.	1.0	17
66	c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. Clinical Colorectal Cancer, 2018, 17, 165-169.	1.0	71
67	The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. Translational Oncology, 2018, 11, 353-357.	1.7	8
68	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 232 Tc colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncology, The, 2018, 19, 660-671.	5.1	107
69	Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. BMC Cancer, 2018, 18, 1103.	1.1	25
70	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. Journal of Gastric Cancer, 2018, 18, 348.	0.9	12
71	Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. Journal of Cancer, 2018, 9, 3394-3399.	1.2	5
72	The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. Journal of Cancer, 2018, 9, 1791-1796.	1.2	7

#	Article	IF	Citations
73	Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. Radiotherapy and Oncology, 2018, 129, 306-312.	0.3	12
74	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nature Medicine, 2018, 24, 1449-1458.	15.2	1,071
75	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. Journal of Cancer, 2018, 9, 2910-2915.	1.2	6
76	Prognostic Role of Carcinoembryonic Antigen Level after Preoperative Chemoradiotherapy in Patients with Rectal Cancer. Journal of Gastrointestinal Surgery, 2018, 22, 1772-1778.	0.9	7
77	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. Journal of Clinical Oncology, 2018, 36, e14501-e14501.	0.8	1
78	Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study. Cancer Research and Treatment, 2018, 50, 175-182.	1.3	18
79	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. Journal of Clinical Oncology, 2018, 36, e24234-e24234.	0.8	0
80	Detection of targetable fusions using FusionPlex in oncology patients.. Journal of Clinical Oncology, 2018, 36, e24238-e24238.	0.8	0
81	A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. Journal of Geriatric Oncology, 2017, 8, 170-175.	0.5	39
82	Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. Oncologist, 2017, 22, 293-303.	1.9	5
83	Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. Investigational New Drugs, 2017, 35, 782-790.	1.2	22
84	Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. BMC Cancer, 2017, 17, 211.	1.1	24
85	A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. Targeted Oncology, 2017, 12, 463-474.	1.7	64
86	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. Oncologist, 2017, 22, 1169-1177.	1.9	14
87	A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. Cancer Chemotherapy and Pharmacology, 2017, 80, 307-315.	1.1	9
88	Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. Molecular and Clinical Oncology, 2017, 7, 27-31.	0.4	15
89	Disappearing or residual tiny (â‰5Âmm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required?. European Radiology, 2017, 27, 3088-3096.	2.3	20
90	Clinical Outcomes of Salvage Chemoradiotherapy for Locally Recurrent Biliary Tract Cancer. Tumori, 2017, 103, 345-352.	0.6	1

#	Article	IF	Citations
91	The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). Journal of Cancer, 2017, 8, 1395-1399.	1.2	20
92	The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. Journal of Cancer, 2017, 8, 2809-2815.	1.2	18
93	The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation. Journal of Cancer, 2017, 8, 2713-2719.	1.2	16
94	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNAâ€"Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. JCO Precision Oncology, 2017, 1, 1-15.	1.5	31
95	Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. Oncotarget, 2017, 8, 11094-11104.	0.8	21
96	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget, 2017, 8, 77415-77423.	0.8	68
97	Phase II XELOX + lapatinib treatment in HER2-amplified gastric cancer: Monitoring with serial cell-free DNA genomics.. Journal of Clinical Oncology, 2017, 35, e15610-e15610.	0.8	1
98	Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study.. Journal of Clinical Oncology, 2017, 35, 671-671.	0.8	2
99	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. Oncotarget, 2017, 8, 3237-3245.	0.8	20
100	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer centerâ€™s experiences. Oncotarget, 2017, 8, 42478-42486.	0.8	32
101	Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. Oncotarget, 2017, 8, 42761-42771.	0.8	34
102	The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. Oncotarget, 2017, 8, 73974-73980.	0.8	5
103	MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. Oncotarget, 2017, 8, 105727-105734.	0.8	16
104	MerTK is a novel therapeutic target in gastric cancer. Oncotarget, 2017, 8, 96656-96667.	0.8	23
105	Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer. Radiation Oncology Journal, 2017, 35, 217-226.	0.7	5
106	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. Journal of Clinical Oncology, 2017, 35, e14622-e14622.	0.8	0
107	The impact of pathologic differentiation (well/ poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.. Journal of Clinical Oncology, 2017, 35, e15686-e15686.	0.8	0
108	Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. Journal of Cancer, 2016, 7, 1044-1048.	1.2	17

#	Article	IF	Citations
109	To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. Journal of Cancer, 2016, 7, 2173-2178.	1.2	1
110	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. Cancer Research and Treatment, 2016, 48, 553-560.	1.3	19
111	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. Journal of Gastric Cancer, 2016, 16, 105.	0.9	34
112	MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. Oncotarget, 2016, 7, 43492-43503.	0.8	45
113	Evaluation of quality of life using a tablet PC-based survey in cancer patients treated with radiotherapy: a multi-institutional prospective randomized crossover comparison of paper and tablet PC-based questionnaires (KROG 12â€"01). Supportive Care in Cancer, 2016, 24, 4399-4406.	1.0	10
114	Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. Chinese Journal of Cancer, 2016, 35, 102.	4.9	12
115	Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. Translational Oncology, 2016, 9, 173-178.	1.7	22
116	A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. Molecular Diagnosis and Therapy, 2016, 20, 375-383.	1.6	13
117	The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. BMC Cancer, 2016, 16, 120.	1.1	35
118	Clinical Significance of Mucinous Rectal Adenocarcinoma following Preoperative Chemoradiotherapy and Curative Surgery. Tumori, 2016, 102, 114-121.	0.6	9
119	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). Journal of Cancer Research and Clinical Oncology, 2016, 142, 1231-1237.	1.2	11
120	Metformin enhances the response to radiotherapy in diabetic patients with rectal cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1377-1385.	1.2	40
121	A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis. Radiotherapy and Oncology, 2016, 118, 369-374.	0.3	24
122	Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Supportive Care in Cancer, 2016, 24, 301-309.	1.0	11
123	Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy. Oncotarget, 2016, 7, 62676-62686.	0.8	6
124	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Oncotarget, 2016, 7, 4024-4035.	0.8	36
125	Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. Oncotarget, 2016, 7, 19610-19619.	0.8	12
126	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. Oncotarget, 2016, 7, 24088-24096.	0.8	15

#	Article	IF	Citations
127	Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. Radiation Oncology Journal, 2016, 34, 34-44.	0.7	10
128	The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. Cancer Research and Treatment, 2016, 48, 153-161.	1.3	11
129	Longitudinal follow-up of quality of life in gastrointestinal cancer patients after curative surgery in South Korea.. Journal of Clinical Oncology, 2016, 34, 697-697.	0.8	0
130	The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution.. Journal of Clinical Oncology, 2016, 34, 4091-4091.	0.8	0
131	The impact of cetuximab plus AKT- or mTOR- inhibitor in patient-derived colon cancer cell model with RAS wild type and PIK3CA mutation.. Journal of Clinical Oncology, 2016, 34, e15153-e15153.	0.8	0
132	Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry. Asia-Pacific Journal of Clinical Oncology, 2015, 11, 334-342.	0.7	7
133	Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. Translational Oncology, 2015, 8, 288-294.	1.7	8
134	Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. BMC Cancer, 2015, 15, 747.	1.1	10
135	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget, 2015, 6, 40360-40369.	0.8	85
136	Immunohistochemical Detection of p53 Expression in Patients with Preoperative Chemoradiation for Rectal Cancer: Association with Prognosis. Yonsei Medical Journal, 2015, 56, 82.	0.9	5
137	Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer. International Journal of Biological Markers, 2015, 30, 382-386.	0.7	25
138	Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer. Cancer Research and Treatment, 2015, 47, 790-795.	1.3	10
139	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget, 2015, 6, 28211-28222.	0.8	57
140	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. Translational Oncology, 2015, 8, 40-46.	1.7	16
141	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. Journal of Clinical Oncology, 2015, 33, 3130-3136.	0.8	370
142	Tumour shrinkage at 6Âweeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer, 2015, 15, 530.	1.1	17
143	A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1015-1022.	0.4	24
144	Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologistâ€™s view of the ARTIST randomized phase III trial. Radiotherapy and Oncology, 2015, 117, 171-177.	0.3	31

#	Article	IF	Citations
145	Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.. Journal of Clinical Oncology, 2015, 33, 2522-2522.	0.8	2
146	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget, 2015, 6, 24320-24332.	0.8	32
147	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget, 2015, 6, 25619-25630.	0.8	48
148	The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. Oncotarget, 2015, 6, 33358-33368.	0.8	24
149	PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. Oncotarget, 2015, 6, 40026-40035.	0.8	15
150	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. Oncotarget, 2015, 6, 39028-39035.	0.8	53
151	Can we omit prophylactic inguinal nodal irradiation in anal cancer patients?. Radiation Oncology Journal, 2015, 33, 83.	0.7	6
152	The efficacy of low-dose transdermal fentanyl in opioid-naÃ¯ve cancer patients with moderate-to-severe pain. Korean Journal of Internal Medicine, 2015, 30, 88.	0.7	12
153	Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. Cancer Research and Treatment, 2015, 47, 738-746.	1.3	10
154	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.. Journal of Clinical Oncology, 2015, 33, 4049-4049.	0.8	2
155	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 3576-3576.	0.8	3
156	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. Journal of Clinical Oncology, 2015, 33, e22241-e22241.	0.8	0
157	S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. BMC Cancer, 2014, 14, 883.	1.1	16
158	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification. Molecular Cancer Therapeutics, 2014, 13, 2527-2536.	1.9	34
159	Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: A phase II multi-institutional clinical trial (KROG 11-02). Radiotherapy and Oncology, 2014, 110, 150-154.	0.3	21
160	Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncology, The, 2014, 15, 1245-1253.	5.1	336
161	Simvastatin plus capecitabineâ€"cisplatin versus placebo plus capecitabineâ€"cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study. European Journal of Cancer, 2014, 50, 2822-2830.	1.3	79
162	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. Scientific Reports, 2014, 4, 7592.	1.6	24

#	Article	IF	Citations
163	Interim safety analysis from a randomized, open-label, multicenter, phase III trial of capecitabine plus oxaliplatin (XELOX) versus capecitabine (X) as first-line chemotherapy in elderly patients with advanced gastric cancer (AGC).. Journal of Clinical Oncology, 2014, 32, 158-158.	0.8	1
164	Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status. PLoS ONE, 2014, 9, e103551.	1.1	21
165	Prognostic and predictive value of liver volume in colorectal cancer patients with unresectable liver metastases. Radiation Oncology Journal, 2014, 32, 77.	0.7	3
166	CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer. Journal of Gastrointestinal Oncology, 2014, 5, 447-56.	0.6	25
167	Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. Cancer Genomics and Proteomics, 2014, 11, 259-66.	1.0	25
168	Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. Anticancer Research, 2014, 34, 6585-91.	0.5	2
169	Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC).. Journal of Clinical Oncology, 2013, 31, 3608-3608.	0.8	3
170	A randomized phase II study of neoadjuvant chemoradiotherapy with 5-FU/leucovorin or irinotecan/S1 in patients with locally advanced rectal cancer.. Journal of Clinical Oncology, 2013, 31, 511-511.	0.8	1
171	A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis.. Journal of Clinical Oncology, 2013, 31, 10589-10589.	0.8	1
172	Open-label, phase IIIb, multicenter, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET).. Journal of Clinical Oncology, 2013, 31, 4138-4138.	0.8	0
173	Pathway redundancy and feedback loop as drivers of nonresponse in colorectal cancer treatments.. Journal of Clinical Oncology, 2013, 31, e14626-e14626.	0.8	0
174	Global clinical experience with adjuvant oxaliplatin/5-fluorouracil (5-FU)-based chemotherapy for colon cancer: Outcomes of the ACCElox registry.. Journal of Clinical Oncology, 2013, 31, e14624-e14624.	0.8	0
175	Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2012, 30, 3531-3531.	0.8	8
176	Perceptions of clinical trials in gastrointestinal/hepatobiliary cancer patients: A comprehensive survey in a Korean tertiary hospital.. Journal of Clinical Oncology, 2012, 30, e13094-e13094.	0.8	0
177	A phase Ib dose escalation study of JX-594 (TK-vaccinia virus expressing GM-CSF) administered by biweekly intravenous infusion in patients with metastatic, refractory colorectal carcinoma.. Journal of Clinical Oncology, 2012, 30, e13044-e13044.	0.8	0
178	A prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver metastasis.. Journal of Clinical Oncology, 2012, 30, e14072-e14072.	0.8	0
179	SSTR2A Protein Expression in Neuroendocrine Neoplasms of the Colorectum. Korean Journal of Pathology, 2011, 45, 276.	1.2	0
180	Importance of the Circumferential Extent of Tumors and Clinical Lymph Node Status as Prognostic Factors after Preoperative Chemoradiotherapy and Surgery in Patients with Rectal Cancer. Tumori, 2010, 96, 568-576.	0.6	9

#	Article	IF	Citations
181	Changes in the Mean Corpuscular Volume after Capecitabine Treatment Are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer. Cancer Research and Treatment, 1970, 47, 72-77.	1.3	20